I was at the four seasons presentation that genr had
a couple of months ago. They said an intranasal version of squalamine is entirely possible, but they would be looking for their partner to fool around with it.
Bentley pharmaceuticals has intranasal technology that would work. I am sure ntsk could do it also. It is a small molecule, it shouldn't be a problem.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.